

# Hemodynamic changes in neonates born to mothers with Graves' disease

メタデータ	言語: eng 出版者: 公開日: 2021-11-16 キーワード (Ja): キーワード (En): 作成者: Ishikawa, Takamichi, Uchiyama, Hiroki, Iwashima, Satoru, Baba, Toru, Ohishi, Akira, Iijima, Shigeo, Itoh, Hiroaki メールアドレス: 所属:
URL	<a href="http://hdl.handle.net/10271/00003928">http://hdl.handle.net/10271/00003928</a>

1 1 **Hemodynamic changes in neonates born to mothers with Graves' disease**

2  
3  
4  
5 2

6  
7  
8 3 Takamichi Ishikawa <sup>1</sup>, MD, PhD, Hiroki Uchiyama <sup>1</sup>, MD, Satoru Iwashima <sup>1</sup>, MD, PhD,

9  
10  
11 4 Toru Baba <sup>1</sup>, MD, Akira Ohishi <sup>1</sup>, MD, PhD, Shigeo Iijima <sup>1</sup>, MD, PhD, Hiroaki Itoh <sup>2</sup>, MD,

12  
13  
14  
15 5 PhD

16  
17  
18  
19 6

20  
21  
22 7 <sup>1</sup> Department of Pediatrics and <sup>2</sup> Department of Obstetrics and Gynecology, Hamamatsu

23  
24  
25  
26 8 University School of Medicine, Japan

27  
28  
29 9

30  
31  
32  
33 10 **Corresponding author:** Takamichi Ishikawa, MD, PhD, Department of Pediatrics,

34  
35  
36 11 Hamamatsu University School of Medicine, 1-20-1 Handayama, Higashi-ku, Hamamatsu

37  
38  
39  
40 12 431-3192, Japan, Tel: +81-053-435-2312, Fax: +81-053-435-2311, E-mail:

41  
42  
43 13 ishikawa@hama-med.ac.jp

44  
45  
46  
47 14

48  
49  
50 15 **Short title:** Hemodynamics in newborns and Graves' disease

51  
52  
53 16

54  
55  
56  
57  
58  
59  
60  
61  
62  
63  
64  
65

1 **Abstract**

2  
3  
4 2 **Purpose:** Cardiac insufficiency is a major morbidity in neonatal hyperthyroidism. It is  
5  
6  
7  
8 3 important to assess the hemodynamics in neonates born to mothers with Graves' disease (GD).  
9  
10  
11 4 This study prospectively evaluated the hemodynamic changes in neonates born to mothers  
12  
13  
14  
15 5 with GD.

16  
17  
18 6 **Methods:** Overall, 80 newborns were enrolled. Thirty-six neonates were born to mothers with  
19  
20  
21  
22 7 GD who were positive for thyroid-stimulating hormone (TSH) receptor antibody (TRAb), and  
23  
24  
25  
26 8 44 were born to mother negative for TRAb. The serum levels of TSH, free triiodothyronine  
27  
28  
29 9 (FT<sub>3</sub>), free thyroxine (FT<sub>4</sub>), and N-terminal-pro-B-type natriuretic peptide (NT-proBNP), the  
30  
31  
32  
33 10 cardiac output, and cardiac index (CI) evaluated by echocardiography were compared  
34  
35  
36  
37 11 between the two groups at several postnatal points (day of delivery and 5, 10, and 30 days of  
38  
39  
40 12 life).

41  
42  
43 13 **Results:** The TRAb-positive newborns had higher FT<sub>4</sub> levels and CI on Day 5 (both p<0.05)  
44  
45  
46  
47 14 and higher FT<sub>3</sub> (p<0.05) and FT<sub>4</sub> levels (p<0.01) and CI (p<0.01) but lower TSH levels  
48  
49  
50  
51 15 (p<0.05) on Day 10 than the TRAb-negative newborns. The TRAb-positive newborns had  
52  
53  
54 16 significantly higher NT-proBNP levels on Days 5 (median 752 vs. 563 pg/mL, p=0.034) and  
55  
56  
57 17 10 (median 789 vs. 552 pg/mL, p=0.002) than the TRAb-negative newborns.  
58  
59  
60  
61  
62  
63  
64  
65

1 **Conclusions:** Hemodynamic changes in neonates born to TRAb-positive mothers with GD  
2  
3  
4  
5 2 resulted in a higher CI and NT-proBNP levels than in those with TRAb-negative mothers  
6  
7  
8 3 from postnatal days 5 to 10.  
9

10  
11 4  
12  
13  
14  
15 5 **Key words:** Neonatal hyperthyroidism; Cardiac Output; N-terminal-pro-B-type natriuretic  
16  
17  
18 6 peptide; Thyroid-stimulating hormone receptor antibody; Echocardiography  
19  
20

21 7  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60  
61  
62  
63  
64  
65

- 1 1 **Declarations**  
2  
3
- 4 2 **Funding:** This work was supported by JSPS KAKENHI Grant Number JP18K07787.  
5  
6  
7  
8 3  
9
- 10  
11  
12 4 **Conflicts of interest:** The authors declare no conflicts of interest.  
13  
14
- 15 5  
16  
17
- 18 6 **Ethics approval:** The study was conducted in accordance with the ethical principles  
19  
20  
21  
22 7 described in the Declaration of Helsinki and was approved by the local ethics committees.  
23  
24  
25 8  
26  
27
- 28 9 **Consent to participate:** Informed consent was obtained from the parents of each newborn.  
29  
30  
31  
32 10  
33  
34  
35
- 36 11 **Consent for publication:** Not applicable.  
37  
38  
39 12  
40  
41  
42
- 43 13 **Availability of data and material:** The datasets during and/or analysed during the current  
44  
45  
46 14 study available from the corresponding author on reasonable request.  
47  
48  
49 15  
50  
51  
52
- 53 16 **Code availability:** Not applicable.  
54  
55  
56 17  
57  
58  
59  
60  
61  
62  
63  
64  
65

1 **Authors' contributions:** TI designed and conducted the research, conducted the statistical  
2  
3  
4 analyses, interpreted the data, and drafted the initial manuscript. HU, SI, TB, and AO made  
5  
6  
7  
8 substantial contributions to the acquisition of data. SI and HI contributed to the study design  
9  
10  
11 and provided comments on the manuscript. All authors revised and approved the final version.  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60  
61  
62  
63  
64  
65

5

1 **1 Introduction**

2  
3  
4 2 Neonatal Graves' hyperthyroidism results from transplacental passage of stimulatory  
5  
6  
7  
8 3 thyroid-stimulating hormone (TSH) receptor antibody (TRAb) from the mother [1-4]. Cardiac  
9  
10  
11 4 insufficiency is a major morbidity in this disease [5] and is associated with the short-term  
12  
13  
14  
15 5 prognosis after birth. Death from congestive heart failure and arrhythmia occurs in severe  
16  
17  
18 6 cases [6]. There are reports of newborn patients with heart failure associated with neonatal  
19  
20  
21  
22 7 hyperthyroidism [7-10]. It is therefore important to assess the hemodynamics in neonates born  
23  
24  
25  
26 8 to mothers with GD. A few reports have evaluated hemodynamics with echocardiography and  
27  
28  
29 9 biomarkers, such as N-terminal-pro-B-type natriuretic peptide (NT-proBNP), in adult patients  
30  
31  
32  
33 10 with thyroid disease [11-13]. However, no previous studies have measured the hemodynamics  
34  
35  
36  
37 11 in neonates born to mothers with thyroid disease. The present study prospectively evaluated  
38  
39  
40 12 the hemodynamic changes in neonates born to mothers with Graves' disease (GD).

41  
42  
43 13  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60  
61  
62  
63  
64  
65

## 1 **Materials and Methods**

### 2 *Subjects*

3 The subjects of this study were neonates born to mothers with GD who became pregnant  
4 between April 2006 and May 2018 and visited Hamamatsu University Hospital. The inclusion  
5 criteria for the mothers were as follows: a past or current history of GD diagnosed by an  
6 endocrinologist based on clinical and laboratory test findings for hyperthyroidism with goiter,  
7 Graves' ophthalmopathy or dermopathy; and at least one positive test for TRAb [14, 15]. No  
8 exclusion criteria for mothers were used. The exclusion criteria for neonates were congenital  
9 heart disease, hemodynamically significant patent ductus arteriosus, and persistent pulmonary  
10 hypertension, all of which cause elevated NT-proBNP levels [16-18].

11 This prospective study included two groups: neonates born to mothers consistently negative  
12 for TRAb in the third trimester of pregnancy, and neonates born to mothers with at least one  
13 positive TRAb assay in the third trimester of pregnancy. For all newborns, the body height  
14 and weight and heart rate (HR) were measured on the day of delivery (Day 0) and at 5 (Day  
15 5), 10 (Day 10), and 30 (Day 30) days of age. All newborns were followed clinically until  
16 three months of age, based on recommendations [19].

17 The study was conducted in accordance with the ethical principles described in the



1 Declaration of Helsinki and was approved by the local ethics committees. Informed consent  
2  
3  
4 was obtained from the parents of each newborn.  
5  
6  
7

8 3

9  
10  
11 4 *Serum measurements*  
12  
13

14  
15 5 The maternal TSH, free triiodothyronine (FT<sub>3</sub>), and free thyroxine (FT<sub>4</sub>) levels were measured,  
16  
17  
18 6 and the TRAb status was assessed in the third trimester of pregnancy. The umbilical cord was  
19  
20  
21  
22 7 doubly clamped immediately after delivery, and arterial blood was drawn for measurement of  
23  
24  
25  
26 8 the pH, serum levels of TSH, FT<sub>3</sub>, FT<sub>4</sub>, and NT-proBNP, and the concentrations of TRAb and  
27  
28  
29 9 thyroid-stimulating antibody (TSAb).  
30  
31

32  
33 10 The serum TSH, FT<sub>3</sub>, and FT<sub>4</sub> levels were assayed using a Roche ECLusys kit (Roche,  
34  
35  
36 11 Basel, Switzerland). The reference ranges in the third trimester were as follows: TSH (mU/L),  
37  
38  
39  
40 12 0.41–4.01; FT<sub>3</sub> (pg/mL), 2.00–4.90; and FT<sub>4</sub> (ng/dL), 0.82–1.63. The plasma NT-proBNP  
41  
42  
43 13 levels were measured using an Elecsys2010 analyzer with a chemiluminescent immunoassay  
44  
45  
46  
47 14 kit (Roche Diagnostics GmbH, Mannheim, Germany). TRAb (normal range, 0%-15%) and  
48  
49  
50  
51 15 TSAb (normal range, <180%) were measured by a commercially available kit (TRAb-CT RIA  
52  
53  
54 16 kit; Cosmic Corporation, Tokyo, Japan; TSAb assay kit; Yamasa Corporation, Tokyo, Japan).  
55  
56  
57 17 Venous blood samples were collected from each neonate on Days 5, 10, and 30 postpartum  
58  
59  
60  
61  
62  
63  
64  
65

1 for a re-assay of the serum TSH, FT<sub>3</sub>, FT<sub>4</sub>, and NT-proBNP levels. The reference ranges of  
2  
3  
4  
5 2 cord blood were as follows: TSH (mU/L), 3.0–30.6; FT<sub>3</sub> (pg/mL), 1.3–2.4; and FT<sub>4</sub> (ng/dL),  
6  
7  
8 3 1.0–1.7. The reference ranges for 5-day-old neonates were as follows: TSH, 0.4–6.0; FT<sub>3</sub>,  
9  
10  
11 4 2.2–5.0; and FT<sub>4</sub>, 1.6–3.2. The reference ranges for 7- to 30-day-old neonates were as  
12  
13  
14  
15 5 follows: TSH, 0.5–4.6; FT<sub>3</sub>, 2.7–4.6; and FT<sub>4</sub>, 1.8–2.9 [20]. The reference values of  
16  
17  
18 6 NT-proBNP (mean ± standard deviation) were 818 ± 546 pg/mL on postnatal day 0 (cord  
19  
20  
21  
22 7 blood), 1731 ± 1236 pg/mL on postnatal days 4–8, and 215 ± 169 pg/mL on postnatal days 9–  
23  
24  
25 8 365 [21]. Hyperthyroidism was defined as either TSH below the lower limit of the reference  
26  
27  
28  
29 9 range or undetectable serum TSH levels, and FT<sub>4</sub> above the upper normal range in cord blood  
30  
31  
32  
33 10 and at 5 and 7-30 days of postnatal life. Subclinical hyperthyroidism was defined as either  
34  
35  
36 11 TSH below the lower limit of the reference range or undetectable TSH levels, and normal  
37  
38  
39  
40 12 serum FT<sub>4</sub> and FT<sub>3</sub> levels. Hypothyroidism was defined as TSH above the upper normal range  
41  
42  
43 13 and FT<sub>4</sub> below the lower limit of the reference range at each point of postnatal life.  
44  
45  
46  
47 14 Subclinical hypothyroidism was defined as TSH above the upper normal range levels with  
48  
49  
50  
51 15 normal serum FT<sub>4</sub> and FT<sub>3</sub> levels. Central hypothyroidism was defined as reduced TSH levels  
52  
53  
54 16 with low serum FT<sub>4</sub> levels, as follows: TSH concentration <20 mU/L in combination with FT<sub>4</sub>  
55  
56  
57 17 concentration <0.9 ng/dL [22] [23].  
58  
59  
60  
61  
62  
63  
64  
65

1

2

3

4

5

6

7

8

9

10

11

12

13

14

15

16

17

18

19

20

21

22

23

24

25

26

27

28

29

30

31

32

33

34

35

36

37

38

39

40

41

42

43

44

45

46

47

48

49

50

51

52

53

54

55

56

57

58

59

60

61

62

63

64

65

## 2 *Echocardiography*

3 An echocardiographic examination was performed on each neonate at Days 0, 5, 10, and 30  
4 with the Philips HD11XE (Philips Medical Systems, Andover, MA, USA) device with an  
5 8-MHz transducer. Various parameters were measured using cross-sectional  
6 echocardiographic images. The left ventricular end-diastolic volume (LVEDV) and left  
7 ventricular end-systolic volume (LVESV) were calculated using the formula of Teichholz et al  
8 [24]. The stroke volume (SV [mL] = LVEDV–LVESV), cardiac output (CO [L/min] = SV ×  
9 HR), and cardiac index (CI [L/min/m<sup>2</sup>] = CO/body surface area) were also evaluated.  
10 Measurement of the HR and the echocardiographic examinations were performed during  
11 natural sleep.

12 The echocardiographic examinations were performed by one of two pediatric cardiologists (T.  
13 I., S. I.). All of the findings from the examinations were recorded and reviewed by another  
14 pediatric cardiologist as a second observer who was blinded to the patients' identifiers.

15

## 16 *Statistical analyses*

17 The data are presented as the mean and standard deviation or median and interquartile range

1 (IQR), as appropriate. The baseline characteristics of the two groups were compared by the  
2  
3  
4  
5 2 two-sided Student's  $t$  test. The Mann-Whitney  $U$ -test was used if the variables were not  
6  
7  
8 3 normally distributed. The chi-square test and Fisher's exact test were used for the qualitative  
9  
10  
11  
12 4 categorical analysis. An analysis of variance (ANOVA) for repeated measures was used to  
13  
14  
15 5 evaluate the differences between the groups and changes over time. When a significant  
16  
17  
18  
19 6 difference was indicated by an ANOVA, the specific source of the difference was identified  
20  
21  
22 7 using either the Mann-Whitney  $U$ -test or a paired  $t$ -test, with Bonferroni's correction. A  
23  
24  
25  
26 8 p-value of less than 0.05 was considered to be statistically significant.  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60  
61  
62  
63  
64  
65

## 1 Results

2  
3  
4 2 During the study period, 86 pregnant women with Graves' disease were seen. Newborns with  
5  
6  
7  
8 3 congenital heart disease (n=3) and hemodynamically significant patent ductus arteriosus  
9  
10  
11 4 (n=3) were excluded. Thus, a total of 80 neonates born to mothers with GD were included in  
12  
13  
14  
15 5 the final analysis. There were 36 neonates born to mothers positive for TRAb and 44 born to  
16  
17  
18 6 mother negative for TRAb. The average gestational age at which the maternal TRAb was  
19  
20  
21  
22 7 evaluated was  $32.3 \pm 3.4$  weeks. The baseline characteristics and laboratory data of all of the  
23  
24  
25  
26 8 mothers and newborns are shown in **Table 1**. The mothers positive for TRAb had  
27  
28  
29 9 significantly higher TRAb, FT<sub>3</sub> (p=0.033), and FT<sub>4</sub> (p=0.027) levels and lower TSH  
30  
31  
32  
33 10 (p=0.001) levels than those negative for TRAb, although these values were within the normal  
34  
35  
36 11 range. The rate of receiving anti-thyroid drug (ATD) in TRAb-positive mothers during  
37  
38  
39  
40 12 pregnancy was significantly higher than in TRAb-negative mothers. In addition, the median  
41  
42  
43 13 prepartum doses of ATD (propylthiouracil) in TRAb-positive mothers (n=16) was 150mg/day  
44  
45  
46  
47 14 (IQR 175mg/day). These doses were significantly higher than those in TRAb-negative  
48  
49  
50  
51 15 mothers (n=10: median, 50mg/day; IQR 75mg/day, p=0.001). The cord blood TRAb and  
52  
53  
54 16 TSAb concentrations were significantly higher in TRAb-positive newborns than in  
55  
56  
57 17 TRAb-negative newborns (p<0.001 and p=0.020, respectively).  
58  
59  
60  
61  
62  
63  
64  
65

1 Table 2 shows the changes in the thyroid function in both groups after birth. At Day 5,  
2  
3  
4 the FT<sub>4</sub> levels in the TRAb-positive newborns were significantly higher than those in the  
5  
6  
7  
8 TRAb-negative newborns ( $p < 0.05$ ). At Day 10, the TRAb-positive newborns had significantly  
9  
10  
11 higher FT<sub>3</sub> ( $p < 0.05$ ) and FT<sub>4</sub> ( $p < 0.01$ ) levels and lower TSH ( $p < 0.05$ ) levels than the  
12  
13  
14  
15 TRAb-negative newborns, although these values were within the normal range. During the  
16  
17  
18  
19 study period, 4 newborns (11.1%) in the TRAb-positive group required treatment with ATD  
20  
21  
22 for overt neonatal hyperthyroidism. Eight newborns (22.2%) in the TRAb-positive group  
23  
24  
25  
26 were diagnosed with subclinical hyperthyroidism based on findings of laboratory tests in the  
27  
28  
29 absence of any clinical symptoms. One neonate in the TRAb-positive group had subclinical  
30  
31  
32  
33 hypothyroidism at birth, but there were no symptoms, so no treatment was required. All of the  
34  
35  
36  
37 remaining newborns had a normal thyroid function in utero based on the findings in their cord  
38  
39  
40 blood at delivery. Detailed information regarding the 12 overt or subclinical hyperthyroid  
41  
42  
43 newborns is provided in **Table 3**. None of the newborns in the TRAb-positive group had  
44  
45  
46  
47 hypothyroidism or central hypothyroidism.

50  
51 Three neonates in the TRAb-negative group, whose mothers received ATD until  
52  
53  
54 delivery, had subclinical hypothyroidism at Day 5, but there were no symptoms, so no  
55  
56  
57  
58 treatment was required. None of the newborns in the TRAb-negative group were diagnosed  
59  
60  
61  
62  
63  
64  
65

1 with hyper- or hypothyroidism. None of the neonates developed clinical symptoms of  
2  
3  
4  
5 2 hyperthyroidism over the first month.  
6  
7

8 3 Table 4 summarizes the changes in the hemodynamic parameters after birth in both  
9  
10  
11 4 groups. The HR and CI at Day 5 were higher in TRAb-positive newborns than in  
12  
13  
14  
15 5 TRAb-negative newborns (both  $p < 0.05$ ). At Day 10, the HR ( $p < 0.05$ ), SV ( $p < 0.05$ ), CO  
16  
17  
18 6 ( $p < 0.05$ ), and CI ( $p < 0.01$ ) were significantly higher in the TRAb-positive newborns than in  
19  
20  
21  
22 7 the TRAb-negative newborns.  
23  
24

25 8 The NT-proBNP levels at Days 5 and 10 were significantly higher in the TRAb-positive  
26  
27  
28  
29 9 newborns (Day 5: median, 752 pg/mL; IQR, 780 pg/mL,  $p = 0.034$  and Day 10: median, 789  
30  
31  
32  
33 10 pg/mL; IQR, 713 pg/mL,  $p = 0.002$ ) than in the TRAb-negative newborns (Day 5: median, 563  
34  
35  
36 11 pg/mL; IQR, 297 pg/mL and Day 10: median, 552 pg/mL; IQR, 384 pg/mL). The median  
37  
38  
39  
40 12 NT-proBNP levels in the TRAb-positive newborns at Days 0 and 30 were 346 (IQR 470)  
41  
42  
43 13 pg/mL and 411 (IQR 491) pg/mL, respectively. The median NT-proBNP levels in the  
44  
45  
46  
47 14 TRAb-negative newborns at Days 0 and 30 were 252 (IQR 347) pg/mL and 396 (IQR 301)  
48  
49  
50  
51 15 pg/mL, respectively. There were no significant differences in those levels between the two  
52  
53  
54 16 groups. In addition, the median NT-proBNP levels significantly increased over the first 10  
55  
56  
57 17 days in the TRAb-positive newborns, while the NT-proBNP levels peaked on Day 5 in the  
58  
59  
60  
61  
62  
63  
64  
65

1 TRAb-negative newborns (**Figure**).

2  
3  
4 2 Table 5 summarizes the changes in the thyroid function and NT-proBNP levels after

5  
6  
7  
8 3 birth in the TRAb-positive newborns without thyroid dysfunction and with hyperthyroidism.

9  
10  
11 4 At Day 0, the TSH level in the newborns with hyperthyroidism was significantly lower than

12  
13  
14  
15 5 those in the newborns without thyroid dysfunction ( $p<0.05$ ). At Day 5, the newborns with

16  
17  
18 6 hyperthyroidism had significantly lower TSH ( $p<0.05$ ) and higher FT<sub>3</sub> ( $p<0.01$ ) and FT<sub>4</sub>

19  
20  
21  
22 7 ( $p<0.01$ ) levels than the newborns without thyroid dysfunction. At Day 10, the newborns with

23  
24  
25 8 hyperthyroidism had significantly lower TSH ( $p<0.05$ ) and higher FT<sub>4</sub> ( $p<0.01$ ) and

26  
27  
28  
29 9 NT-proBNP ( $p<0.01$ ) levels than the newborns without thyroid dysfunction.

30  
31  
32 10

33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60  
61  
62  
63  
64  
65



1 **Discussion**

2  
3  
4 2 This is the first report concerning the hemodynamic changes in neonates born to mothers with  
5  
6  
7  
8 3 GD. The present study showed that the neonates born to GD mothers positive for TRAb had  
9  
10  
11 4 significantly higher CO, CI, and NT-proBNP levels from postnatal days 5 to 10 than those  
12  
13  
14  
15 5 born to GD mothers negative for TRAb.  
16  
17

18  
19 6 In the present study, the FT<sub>4</sub> levels at Day 5 in newborns positive for TRAb were  
20  
21  
22 7 significantly higher than those in newborns negative for TRAb. Furthermore, the newborns  
23  
24  
25  
26 8 positive for TRAb had significantly higher FT<sub>3</sub> and FT<sub>4</sub> levels and lower TSH values at Day  
27  
28  
29 9 10 than did the newborns negative for TRAb. This difference in thyroid function parameters  
30  
31  
32  
33 10 between the two groups was most marked at Day 10, possibly owing to the balance of  
34  
35  
36  
37 11 maternal TRAb and ATD. Neonates born to GD mothers treated with ATD may be  
38  
39  
40 12 hyperthyroid until approximately 7 to 10 days after birth, while they can be euthyroid or even  
41  
42  
43 13 hypothyroid at birth [25]. In the current study, the rate of mothers who received ATD in the  
44  
45  
46  
47 14 TRAb-positive group was significantly higher than that in TRAb-negative group. These  
48  
49  
50  
51 15 results indicated the greater thyroid function in TRAb-positive newborns from postnatal days  
52  
53  
54 16 5 to 10.

55  
56  
57 17 Our study showed that the HR, SV, CO, and CI as well as the FT<sub>4</sub> levels at Day 10 were  
58  
59  
60  
61  
62  
63  
64  
65

1 significantly higher in the TRAb-positive newborns than in the TRAb-negative newborns.  
2  
3  
4 2 The NT-proBNP levels at Day 10 in the TRAb-positive newborns were also significantly  
5  
6  
7  
8 3 higher than those in the TRAb-negative newborns. Of note, the TRAb-positive newborns with  
9  
10  
11 4 hyperthyroidism had significantly higher NT-proBNP levels at Day 10 than the  
12  
13  
14  
15 5 TRAb-positive newborns without thyroid dysfunction. Thyroid hormone levels increase the  
16  
17  
18 6 blood volume and CO [26-28]. In addition, a combination of reduced systemic vascular  
19  
20  
21  
22 7 resistance and increased venous return, blood volume, myocardial contractility, and oxygen  
23  
24  
25  
26 8 consumption leads to a reduced functional cardiac reserve and decreased exercise capacity  
27  
28  
29 9 because of an inadequate increase in CO [29]. NT-proBNP, which is produced in ventricular  
30  
31  
32  
33 10 cardiomyocytes and secreted in response to volume expansion or pressure overload, is a  
34  
35  
36 11 useful tool for both diagnosing and monitoring cardiac insufficiency and heart failure [30-32].  
37  
38  
39  
40 12 Clinical evidence has shown that the serum levels of NT-proBNP are strongly affected by the  
41  
42  
43 13 thyroid function; the higher the thyroid function, the higher the NT-proBNP level [33]. Kohno  
44  
45  
46  
47 14 et al. suggested that a potential mechanism for this situation is the influence of secondary  
48  
49  
50  
51 15 hemodynamic changes accompanied by hyperthyroidism on the release of BNP [34]. The  
52  
53  
54 16 results in this study suggested that the elevation of the NT-proBNP levels in TRAb-positive  
55  
56  
57 17 patients was caused by an increased CO, which resulted from an elevated thyroid function.  
58  
59  
60  
61  
62  
63  
64  
65

1           The plasma NT-proBNP levels in healthy newborns are highest on Day 1. After this  
2  
3  
4           2    marked increase, the NT-proBNP levels rapidly decrease and become stable at the third day of  
5  
6  
7  
8           3    life [21, 35]. However, in our study, the NT-proBNP levels in the TRAb-positive newborns  
9  
10  
11           4    significantly increased over the first 10 days after birth. This finding suggests that these  
12  
13  
14  
15           5    hemodynamic changes are associated with elevated thyroid hormone levels. In the present  
16  
17  
18           6    study, a relatively large number of newborns positive for TRAb were diagnosed with  
19  
20  
21  
22           7    subclinical hyperthyroidism. However, the newborns positive for TRAb had significantly  
23  
24  
25           8    higher CO, CI, and NT-proBNP values than those negative for TRAb from Days 5 to 10.  
26  
27  
28           9    Subclinical hyperthyroidism is associated with an increased HR and left ventricular mass with  
29  
30  
31  
32           10   marginal concentric remodeling and impaired ventricular relaxation [36]. Previous studies  
33  
34  
35           11   have also shown that patients with subclinical hyperthyroidism had significantly higher CO  
36  
37  
38           12   and serum NT-proBNP values than controls or the same patients after treatment [27, 33, 37].  
39  
40  
41           13   The findings of the present study are compatible with these previous results. Our study  
42  
43  
44           14   suggests that neonates born to GD mothers with a high titer of TRAb are at risk of cardiac  
45  
46  
47           15   complications associated with neonatal Graves' hyperthyroidism, such as high-output heart  
48  
49  
50           16   failure, during the first 10 days after birth.  
51  
52  
53

54           17    There are several limitations in the present study, such as the small sample size, with a  
55  
56  
57  
58  
59  
60  
61  
62  
63  
64  
65

1 small number of newborns having overt hyperthyroidism. In addition, this study did not have  
2  
3  
4 2 a normal control group, which precludes the comparison of hemodynamics between neonates  
5  
6  
7  
8 3 born to mothers with and without GD. However, neonates born to mother negative for TRAb  
9  
10  
11 4 and without ATD treatment might constitute a control group. Future studies with larger  
12  
13  
14  
15 5 populations and a control group may help clarify the hemodynamics in neonates born to  
16  
17  
18 6 mothers with GD in greater detail.  
19  
20  
21

22 7 In conclusion, the hemodynamic changes in neonates born to mothers with GD who are  
23  
24  
25 8 positive for TRAb result in significantly higher CO, CI, and NT-proBNP values from  
26  
27  
28  
29 9 postnatal days 5 to 10 than those born to GD mothers who are negative for TRAb. Therefore,  
30  
31  
32 10 physicians should carefully monitor the signs and symptoms related to cardiac complications  
33  
34  
35  
36 11 to help prevent high-output heart failure associated with neonatal GD, especially during the  
37  
38  
39  
40 12 first 10 days after birth.  
41  
42  
43  
44

45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60  
61  
62  
63  
64  
65

1 **1 Acknowledgements**

2

3

4

5

6

7

8

9

10

11

12

13

14

15

16

17

18

19

20

21

22

23

24

25

26

27

28

29

30

31

32

33

34

35

36

37

38

39

40

41

42

43

44

45

46

47

48

49

50

51

52

53

54

55

56

57

58

59

60

61

62

63

64

65

2 The authors thank Dr. Masaki Yamamoto, Department of Pediatrics, Seirei Hamamatsu

3 General Hospital, Dr. Shinichi Nakashima, JA Shizuoka Kohseiren Enhu Hospital, and Dr.

4 Jiro Kagawa, Fujieda Municipal General Hospital, for their valuable assistance.

5

1   1   **References**

- 2  
3  
4   2   1.       Sunshine P, Kusumoto H, Kriss JP: Survival time of circulating  
5  
6  
7  
8   3   long-acting thyroid stimulator in neonatal thyrotoxicosis: implications for  
9  
10  
11   4   diagnosis and therapy of the disorder. *Pediatrics* 36(6), 869-876 (1965).  
12  
13  
14  
15   5   2.       McKenzie JM, Zakarija M: Fetal and neonatal hyperthyroidism and  
16  
17  
18   6   hypothyroidism due to maternal TSH receptor antibodies. *Thyroid* 2(2), 155-159  
19  
20  
21  
22   7   (1992). doi:10.1089/thy.1992.2.155  
23  
24  
25   8   3.       Laurberg P, Bournaud C, Karmisholt J, Orgiazzi J: Management of  
26  
27  
28   9   Graves' hyperthyroidism in pregnancy: focus on both maternal and foetal thyroid  
29  
30  
31  
32   10   function, and caution against surgical thyroidectomy in pregnancy. *Eur J*  
33  
34  
35  
36   11   *Endocrinol* 160(1), 1-8 (2009). doi:10.1530/eje-08-0663  
37  
38  
39  
40   12   4.       Zimmerman D: Fetal and neonatal hyperthyroidism. *Thyroid* 9(7),  
41  
42  
43   13   727-733 (1999). doi:10.1089/thy.1999.9.727  
44  
45  
46  
47   14   5.       Polak M: Hyperthyroidism in early infancy: pathogenesis, clinical  
48  
49  
50   15   features and diagnosis with a focus on neonatal hyperthyroidism. *Thyroid* 8(12),  
51  
52  
53  
54   16   1171-1177 (1998). doi:10.1089/thy.1998.8.1171  
55  
56  
57   17   6.       Radetti G, Zavallone A, Gentili L, Beck-Peccoz P, Bona G: Foetal and  
58  
59  
60  
61  
62  
63  
64  
65

- 1 neonatal thyroid disorders. *Minerva Pediatr* 54(5), 383-400 (2002).
- 2  
3
- 4 2 7. Lightner ES, Allen HD, Loughlin G: Neonatal hyperthyroidism and heart  
5  
6  
7  
8 3 failure. A differential approach. *Am J Dis Child* 131(1), 68-70 (1977).  
9  
10  
11 4 doi:10.1001/archpedi.1977.02120140070012  
12  
13  
14
- 15 5 8. Bussmann YL, Tillman ML, Pagliara AS: Neonatal thyrotoxicosis  
16  
17  
18 6 associated with the hyperviscosity syndrome. *J Pediatr* 90(2), 266-268 (1977).  
19  
20  
21 7 doi:10.1016/s0022-3476(77)80648-3  
22  
23  
24
- 25 8 9. O'Donovan D, McMahon C, Costigan C, Oslizlok P, Duff D: Reversible  
26  
27  
28 9 pulmonary hypertension in neonatal Graves disease. *Ir Med J* 90(4), 147-148  
29  
30  
31 10 (1997).  
32  
33  
34  
35
- 36 11 10. Zuppa AA, Sindico P, Savarese I, D'Andrea V, Fracchiolla A, Cota F,  
37  
38  
39 12 Romagnoli C: Neonatal hyperthyroidism: neonatal clinical course of two brothers  
40  
41  
42 13 born to a mother with Graves-Basedow disease, before and after total  
43  
44  
45  
46 14 thyroidectomy. *J Pediatr Endocrinol Metab* 20(4), 535-539 (2007).  
47  
48  
49 15 doi:10.1515/jpem.2007.20.4.535  
50  
51  
52  
53
- 54 16 11. Gu LQ, Zhao L, Zhu W, Li FY, Zhang MJ, Liu Y, Liu JM, Ning G, Zhao YJ:  
55  
56  
57 17 Relationships between serum levels of thyroid hormones and serum  
58  
59  
60  
61  
62  
63  
64  
65

- 1 concentrations of asymmetric dimethylarginine (ADMA) and  
2  
3  
4  
5 2 N-terminal-pro-B-type natriuretic peptide (NT-proBNP) in patients with Graves'  
6  
7  
8 3 disease. *Endocrine* 39(3), 266-271 (2011). doi:10.1007/s12020-011-9436-7  
9  
10  
11 4 12. Arikan S, Tuzcu A, Gokalp D, Bahceci M, Danis R: Hyperthyroidism may  
12  
13  
14  
15 5 affect serum N-terminal pro-B-type natriuretic peptide levels independently of  
16  
17  
18 6 cardiac dysfunction. *Clin Endocrinol (Oxf)* 67(2), 202-207 (2007).  
19  
20  
21  
22 7 doi:10.1111/j.1365-2265.2007.02861.x  
23  
24  
25  
26 8 13. Ozmen B, Ozmen D, Parildar Z, Mutaf I, Bayindir O: Serum  
27  
28  
29 9 N-terminal-pro-B-type natriuretic peptide (NT-pro-BNP) levels in  
30  
31  
32  
33 10 hyperthyroidism and hypothyroidism. *Endocr Res* 32(1-2), 1-8 (2007).  
34  
35  
36 11 doi:10.1080/07435800701670047  
37  
38  
39  
40 12 14. Massart C, Orgiazzi J, Maugendre D: Clinical validity of a new  
41  
42  
43 13 commercial method for detection of TSH-receptor binding antibodies in sera from  
44  
45  
46  
47 14 patients with Graves' disease treated with antithyroid drugs. *Clin Chim Acta*  
48  
49  
50  
51 15 304(1-2), 39-47 (2001). doi:10.1016/s0009-8981(00)00385-5  
52  
53  
54 16 15. Weetman AP: Graves' disease. *N Engl J Med* 343(17), 1236-1248 (2000).  
55  
56  
57 17 doi:10.1056/nejm200010263431707  
58  
59  
60  
61  
62  
63  
64  
65



- 1 16. Lechner E, Wiesinger-Eidenberger G, Wagner O, Weissensteiner M,  
2  
3  
4 2 Schreier-Lechner E, Leibetseder D, Arzt W, Tulzer G: Amino terminal pro B-type  
5  
6  
7  
8 3 natriuretic peptide levels are elevated in the cord blood of neonates with  
9  
10  
11 4 congenital heart defect. *Pediatr Res* 66(4), 466-469 (2009).  
12  
13  
14  
15 5 doi:10.1203/PDR.0b013e3181b3aee4  
16  
17  
18 6 17. Farombi-Oghuvbu I, Matthews T, Mayne PD, Guerin H, Corcoran JD:  
19  
20  
21  
22 7 N-terminal pro-B-type natriuretic peptide: a measure of significant patent ductus  
23  
24  
25 8 arteriosus. *Arch Dis Child Fetal Neonatal Ed* 93(4), F257-260 (2008).  
26  
27  
28  
29 9 doi:10.1136/adc.2007.120691  
30  
31  
32  
33 10 18. Reynolds EW, Ellington JG, Vranicar M, Bada HS: Brain-type natriuretic  
34  
35  
36 11 peptide in the diagnosis and management of persistent pulmonary hypertension  
37  
38  
39  
40 12 of the newborn. *Pediatrics* 114(5), 1297-1304 (2004). doi:10.1542/peds.2004-0525  
41  
42  
43 13 19. van der Kaay DC, Wasserman JD, Palmert MR: Management of  
44  
45  
46  
47 14 Neonates Born to Mothers With Graves' Disease. *Pediatrics* 137(4) (2016).  
48  
49  
50  
51 15 doi:10.1542/peds.2015-1878  
52  
53  
54 16 20. Tajima T, Jo W, Fujikura K, Fukushi M, Fujieda K: Elevated free  
55  
56  
57 17 thyroxine levels detected by a neonatal screening system. *Pediatr Res* 66(3),  
58  
59  
60  
61  
62  
63  
64  
65

- 1 1 312-316 (2009). doi:10.1203/PDR.0b013e3181b1bcbd  
2  
3
- 4 2 21. Schwachtgen L, Herrmann M, Georg T, Schwarz P, Marx N, Lindinger A:  
5  
6  
7  
8 3 Reference values of NT-proBNP serum concentrations in the umbilical cord blood  
9  
10  
11 4 and in healthy neonates and children. *Z Kardiol* 94(6), 399-404 (2005).  
12  
13  
14  
15 5 doi:10.1007/s00392-005-0246-x  
16  
17
- 18 6 22. Mitsuda N, Tamaki H, Amino N, Hosono T, Miyai K, Tanizawa O: Risk  
19  
20  
21  
22 7 factors for developmental disorders in infants born to women with Graves disease.  
23  
24  
25  
26 8 *Obstet Gynecol* 80(3 Pt 1), 359-364 (1992).  
27  
28
- 29 9 23. Kempers MJ, van Tijn DA, van Trotsenburg AS, de Vijlder JJ, Wiedijk  
30  
31  
32  
33 10 BM, Vulsma T: Central congenital hypothyroidism due to gestational  
34  
35  
36 11 hyperthyroidism: detection where prevention failed. *J Clin Endocrinol Metab*  
37  
38  
39  
40 12 88(12), 5851-5857 (2003). doi:10.1210/jc.2003-030665  
41  
42
- 43 13 24. Teichholz LE, Kreulen T, Herman MV, Gorlin R: Problems in  
44  
45  
46  
47 14 echocardiographic volume determinations: echocardiographic-angiographic  
48  
49  
50  
51 15 correlations in the presence of absence of asynergy. *Am J Cardiol* 37(1), 7-11  
52  
53  
54 16 (1976). doi:10.1016/0002-9149(76)90491-4  
55  
56
- 57 17 25. Zakarija M, McKenzie JM, Hoffman WH: Prediction and therapy of  
58  
59  
60  
61  
62  
63  
64  
65

- 1 1 intrauterine and late-onset neonatal hyperthyroidism. *J Clin Endocrinol Metab*  
2  
3  
4 2 62(2), 368-371 (1986). doi:10.1210/jcem-62-2-368  
5  
6  
7  
8 3 26. Schultz M, Kistorp C, Langdahl B, Raymond I, Hildebrandt P, Faber J:  
9  
10  
11 4 N-terminal-pro-B-type natriuretic peptide in acute hyperthyroidism. *Thyroid*  
12  
13  
14  
15 5 17(3), 237-241 (2007). doi:10.1089/thy.2006.0258  
16  
17  
18  
19 6 27. Faber J, Wiinberg N, Schifter S, Mehlsen J: Haemodynamic changes  
20  
21  
22 7 following treatment of subclinical and overt hyperthyroidism. *Eur J Endocrinol*  
23  
24  
25  
26 8 145(4), 391-396 (2001). doi:10.1530/eje.0.1450391  
27  
28  
29  
30 9 28. Klein I, Ojamaa K: Thyroid hormone and the cardiovascular system. *N*  
31  
32  
33 10 *Engl J Med* 344(7), 501-509 (2001). doi:10.1056/nejm200102153440707  
34  
35  
36  
37 11 29. Franklyn JA, Boelaert K: Thyrotoxicosis. *Lancet* 379(9821), 1155-1166  
38  
39  
40 12 (2012). doi:10.1016/s0140-6736(11)60782-4  
41  
42  
43  
44 13 30. Hobbs FD, Davis RC, Roalfe AK, Hare R, Davies MK, Kenkre JE:  
45  
46  
47 14 Reliability of N-terminal pro-brain natriuretic peptide assay in diagnosis of heart  
48  
49  
50  
51 15 failure: cohort study in representative and high risk community populations. *Bmj*  
52  
53  
54 16 324(7352), 1498 (2002). doi:10.1136/bmj.324.7352.1498  
55  
56  
57  
58 17 31. Gardner RS, Ozalp F, Murday AJ, Robb SD, McDonagh TA: N-terminal  
59  
60  
61  
62  
63  
64  
65

- 1 1 pro-brain natriuretic peptide. A new gold standard in predicting mortality in  
2  
3  
4 2 patients with advanced heart failure. *Eur Heart J* 24(19), 1735-1743 (2003).  
5  
6  
7  
8 3 doi:10.1016/j.ehj.2003.07.005  
9  
10  
11 4 32. Costello-Boerrigter LC, Boerrigter G, Redfield MM, Rodeheffer RJ,  
12  
13  
14  
15 5 Urban LH, Mahoney DW, Jacobsen SJ, Heublein DM, Burnett JC, Jr.:  
16  
17  
18 6 Amino-terminal pro-B-type natriuretic peptide and B-type natriuretic peptide in  
19  
20  
21  
22 7 the general community: determinants and detection of left ventricular  
23  
24  
25 8 dysfunction. *J Am Coll Cardiol* 47(2), 345-353 (2006).  
26  
27  
28  
29 9 doi:10.1016/j.jacc.2005.09.025  
30  
31  
32  
33 10 33. Schultz M, Faber J, Kistorp C, Jarlov A, Pedersen F, Wiinberg N,  
34  
35  
36 11 Hildebrandt P: N-terminal-pro-B-type natriuretic peptide (NT-pro-BNP) in  
37  
38  
39  
40 12 different thyroid function states. *Clin Endocrinol (Oxf)* 60(1), 54-59 (2004).  
41  
42  
43 13 doi:10.1111/j.1365-2265.2004.01941.x  
44  
45  
46  
47 14 34. Kohno M, Horio T, Yasunari K, Yokokawa K, Ikeda M, Kurihara N,  
48  
49  
50  
51 15 Nishizawa Y, Morii H, Takeda T: Stimulation of brain natriuretic peptide release  
52  
53  
54 16 from the heart by thyroid hormone. *Metabolism* 42(8), 1059-1064 (1993).  
55  
56  
57 17 doi:10.1016/0026-0495(93)90023-h  
58  
59  
60  
61  
62  
63  
64  
65

- 1 35. Mir TS, Laux R, Hellwege HH, Liedke B, Heinze C, von Buelow H, Laer S,  
2  
3  
4  
5 2 Weil J: Plasma concentrations of aminoterminal pro atrial natriuretic peptide and  
6  
7  
8 3 aminoterminal pro brain natriuretic peptide in healthy neonates: marked and  
9  
10  
11  
12 4 rapid increase after birth. *Pediatrics* 112(4), 896-899 (2003).  
13  
14  
15 5 doi:10.1542/peds.112.4.896  
16  
17  
18 6 36. Biondi B, Palmieri EA, Lombardi G, Fazio S: Effects of subclinical  
19  
20  
21  
22 7 thyroid dysfunction on the heart. *Ann Intern Med* 137(11), 904-914 (2002).  
23  
24  
25  
26 8 doi:10.7326/0003-4819-137-11-200212030-00011  
27  
28  
29 9 37. Tadic M, Ilic S, Cuspidi C, Marjanovic T, Celic V: Subclinical  
30  
31  
32  
33 10 hyperthyroidism impacts left ventricular deformation: 2D and 3D  
34  
35  
36 11 echocardiographic study. *Scand Cardiovasc J* 49(2), 74-81 (2015).  
37  
38  
39  
40 12 doi:10.3109/14017431.2015.1015441  
41  
42  
43 13  
44  
45  
46 14  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60  
61  
62  
63  
64  
65

1 **Figure Legends**

2  
3  
4  
5 **2 Figure.** Box plots showing the distribution of NT-proBNP in both groups at Days 0 (cord  
6  
7  
8  
9  
10  
11  
12 **3** blood), 5, 10, and 30. The upper boundary of the box represents the 75<sup>th</sup> percentile, and the  
13  
14  
15 **4** lower boundary of the box represents the 25<sup>th</sup> percentile. The line through each box represents  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60  
61  
62  
63  
64  
65  
**5** the median value in each group.

**Figure**




Table 1. The clinical and biological characteristics of the mothers and their newborns

	TRAb-negative (n=44)	TRAb-positive (n=36)	P value
<b><u>Maternal characteristics</u></b>			
Age (years)	33.5 ± 5.4	31.3 ± 5.4	0.069
Maternal TRAb (%)	5.9* (11.6)	30.1* (18.8)	<0.001
Maternal TSH (mU/L)	1.20* (1.15)	0.44* (0.62)	0.001
Maternal FT <sub>3</sub> (pg/mL)	2.0* (0.6)	2.5* (1.0)	0.033
Maternal FT <sub>4</sub> (ng/dL)	1.0* (0.2)	1.3* (0.6)	0.007
Treatment before pregnancy			
Thyroidectomy	1 (2.3%)	4 (11.1%)	0.169
Radioiodine	0 (0.0%)	4 (11.1%)	0.037
ATD	11 (25.9%)	20 (55.6%)	0.005
Treatment during pregnancy			
No treatment	28 (63.6%)	16 (44.4%)	0.086
Methimazole	1 (2.3%)	3 (8.3%)	0.322
Propylthiouracil	9 (20.5%)	13 (36.1%)	0.138
Levothyroxine	8 (18.2%)	9 (25.0%)	0.585
Maternal ATD during pregnancy			
1st trimester	13 (29.5%)	20 (55.6%)	0.019
2nd trimester	11 (25.0%)	16 (44.4%)	0.067
3rd trimester	10 (22.7%)	16 (44.4%)	0.039
<b><u>Newborn characteristics</u></b>			
Male:Female	19:25	17:19	0.718
Gestational age (weeks)	39.1 ± 1.3	39.2 ± 1.4	0.701
Birth weight (grams)	2901 ± 337	2888 ± 366	0.864
Apgar score at 1 min	8.2 ± 1.2	8.3 ± 1.3	0.732
Apgar score at 5 min	9.1 ± 0.8	9.0 ± 1.2	0.752
Cord blood pH	7.279 ± 0.091	7.300 ± 0.126	0.391
Cord blood TRAb (%)	4.0* (10.7)	26.0* (17.1)	<0.001
Cord blood TSAb (%)	111* (44)	227* (163)	0.020

Values are expressed as the mean ± standard deviation.

\* Values are expressed as the median (interquartile range).

A mother may have received more than one treatment.

ATD, anti-thyroid drug (propylthiouracil or methimazole); TSH, thyroid-stimulating hormone; TRAb, TSH-receptor antibody; FT<sub>3</sub>, free triiodothyronine; FT<sub>4</sub>, free thyroxine; TSAb, thyroid-stimulating antibody



Table 2. Changes in the thyroid function after birth in both groups

	Day 0 (Cord blood)	Day 5	Day 10	Day 30
TSH (mU/L)				
TRAb-negative	9.18* (4.23)	5.01* (5.55)	4.25* (1.40)	3.84* (2.99)
TRAb-positive	5.31* (5.42)	2.98* (3.56)	2.40* (1.05) <sup>#</sup>	2.49* (1.01)
FT <sub>3</sub> (pg/mL)				
TRAb-negative	1.4 ± 0.2	3.6 ± 0.7	3.9 ± 0.6	4.2 ± 0.3
TRAb-positive	1.4 ± 0.2	4.0 ± 0.8	4.3 ± 0.5 <sup>#</sup>	4.2 ± 0.6
FT <sub>4</sub> (ng/dL)				
TRAb-negative	1.2 ± 0.1	2.3 ± 0.4	1.8 ± 0.2	1.5 ± 0.2
TRAb-positive	1.1 ± 0.3	2.6 ± 0.4 <sup>#</sup>	2.1 ± 0.4 <sup>##</sup>	1.5 ± 0.2

Values are expressed as the mean ± standard deviation.

\* Values are expressed as the median (interquartile range).

<sup>#</sup> P < .05; <sup>##</sup> P < .01 TRAb-negative versus TRAb-positive.

TSH, thyroid-stimulating hormone; FT<sub>3</sub>, free triiodothyronine; FT<sub>4</sub>, free thyroxine

Table 3. TRAb, TSAb and the thyroid function after birth in newborns with overt or subclinical hyperthyroidism

	Day 0 (Cord blood)					Day 5			Day 10		
	TRAb (%)	TSAb (%)	TSH (mU/L)	FT <sub>3</sub> (pg/mL)	FT <sub>4</sub> (ng/dL)	TSH (mU/L)	FT <sub>3</sub> (pg/mL)	FT <sub>4</sub> (ng/dL)	TSH (mU/L)	FT <sub>3</sub> (pg/mL)	FT <sub>4</sub> (ng/dL)
<b>Overt hyperthyroidism</b>											
Case 1	49.9	434	0.97	0.8	0.8	1.98	3.0	1.9	0.48	4.4	3.0
Case 2	52.9	552	0.82	1.3	1.4	0.18	4.2	2.9	0.08	5.5	3.4
Case 3	76.2	1139	0.01	2.0	1.8	0.34	5.5	4.3	0.44	5.6	3.1
Case 4	91.4	3917	1.64	1.7	1.0	0.17	9.8	7.8	0.02	5.2	2.5
<b>Subclinical hyperthyroidism</b>											
Case 5	37.1	322	2.46	1.6	0.9	6.88	4.4	3.0	2.36	3.5	1.9
Case 6	37.2	441	2.92	2.0	1.5	5.64	4.8	3.1	3.38	4.1	2.8
Case 7	40.5	346	2.02	1.9	1.7	1.24	4.5	3.2	4.11	3.2	2.4
Case 8	37.0	323	1.91	1.8	1.3	6.33	3.9	2.8	2.99	4.4	2.5
Case 9	47.7	305	3.09	2.1	1.7	0.53	5.0	2.9	0.49	4.5	2.9
Case 10	48.0	446	3.21	1.1	1.2	1.29	4.6	2.9	0.48	4.2	2.9
Case 11	42.0	378	2.14	1.4	1.2	0.39	4.0	3.1	0.44	4.6	2.6
Case 12	37.2	311	1.78	2.0	1.6	4.46	3.9	3.0	3.54	3.3	2.7

TRAb, TSH-receptor antibody; TSH, thyroid-stimulating hormone; FT<sub>3</sub>, free triiodothyronine; FT<sub>4</sub>, free thyroxine; TSAb, thyroid-stimulating antibody

Table 4. Changes in the hemodynamic parameters after birth in both groups

	Day 0	Day 5	Day 10	Day 30
HR (bpm)				
TRAb-negative	142 ± 8.4	132 ± 8.0	126 ± 8.2	114 ± 10.0
TRAb-positive	143 ± 8.9	137 ± 6.7 <sup>#</sup>	135 ± 10.7 <sup>#</sup>	119 ± 15.4
SV (mL)				
TRAb-negative	5.8 ± 1.1	5.7 ± 0.9	6.3 ± 0.5	6.7 ± 0.8
TRAb-positive	5.3 ± 1.2	6.4 ± 1.2	7.1 ± 1.2 <sup>#</sup>	6.9 ± 1.3
CO (mL/min)				
TRAb-negative	812 ± 194	758 ± 133	739 ± 115	722 ± 47
TRAb-positive	802 ± 155	878 ± 210	890 ± 161 <sup>#</sup>	790 ± 129
CI (L/min/m <sup>2</sup> )				
TRAb-negative	4.1 ± 0.9	3.9 ± 0.7	3.8 ± 0.6	3.7 ± 0.4
TRAb-positive	4.0 ± 1.1	4.6 ± 1.0 <sup>#</sup>	4.7 ± 0.9 <sup>##</sup>	4.1 ± 0.8

Values are expressed as the mean ± standard deviation.

<sup>#</sup>P < .05; <sup>##</sup>P < .01 TRAb-negative versus TRAb-positive.

HR, heart rate; SV, stroke volume; CO, cardiac output; CI, cardiac index

Table 5. Changes in the thyroid function and NT-proBNP levels after birth in the TRAb-positive newborns without thyroid dysfunction and with hyperthyroidism

	Day 0 (Cord blood)	Day 5	Day 10	Day 30
<b>TSH (mU/L)</b>				
without thyroid dysfunction	10.50* (18.44)	5.69* (3.83)	2.76* (1.83)	3.01* (1.54)
hyperthyroidism	1.97* (1.10)#	1.27* (4.38)#	0.49* (2.65)#	1.86* (1.26)
<b>FT<sub>3</sub> (pg/mL)</b>				
without thyroid dysfunction	1.3 ± 0.5	3.6 ± 0.4	4.2 ± 0.5	4.3 ± 0.6
hyperthyroidism	1.6 ± 0.6	4.8 ± 1.7##	4.4 ± 0.8	3.9 ± 0.6
<b>FT<sub>4</sub> (ng/dL)</b>				
without thyroid dysfunction	1.1 ± 0.5	2.3 ± 0.5	1.8 ± 0.3	1.5 ± 0.2
hyperthyroidism	1.3 ± 0.4	3.4 ± 1.5##	2.7 ± 0.4##	1.4 ± 0.3
<b>NT-proBNP (pg/mL)</b>				
without thyroid dysfunction	372* (609)	686* (949)	582* (780)	348* (458)
hyperthyroidism	293* (377)	794* (555)	1030* (913)#	588* (478)

Values are expressed as the mean ± standard deviation.

\* Values are expressed as the median (interquartile range).

# P < .05; ## P < .01 without thyroid dysfunction versus hyperthyroidism.

TSH, thyroid-stimulating hormone; FT<sub>3</sub>, free triiodothyronine; FT<sub>4</sub>, free thyroxine; NT-proBNP, N-terminal-pro-B-type natriuretic peptide